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HCV recurrence occurs earlier in patients receiving donation after circulatory death (DCD) liver 
transplants compared with those receiving donation after brainstem death (DBD) grafts. 
 
Abstract 
Introduction: HCV-related cirrhosis remains the commonest indication for liver transplantation 
worldwide, yet few studies have investigated the impact of DCD graft use on HCV recurrence and 
patient outcomes. DCD grafts have augmented the limited donor organ pool and reduced wait-list 
mortality, although concerns regarding graft longevity and patient outcome persist. 
Methods: This was a single centre study of all HCV+ adults who underwent DCD liver transplantation 
between 2004 and 2014. 44 HCV+ patients received DCD grafts, and were matched with 44 HCV+ 
recipients of DBD grafts, and their outcomes examined. 
Results: The groups were matched for age, sex, presence of HCC; no significant differences were found 
between the group’s donor or recipient characteristics.  Paired and unpaired analysis demonstrated that 
HCV recurrence was more rapid in recipients of DCD organs compared with DBD grafts (408 vs 657 days; 
p=0.006). There were no significant differences in graft survival, patient survival, or rates of biliary 
complications between the cohorts despite DCD donors being 10 years older on average than those 
used in other published experience. 
Conclusions: In an era of highly effective DAA therapy, rapid HCV recrudescence in grafts from DCD 
donors should not compromise long term morbidity or mortality.  In the context of a rising wait-list 
mortality it is prudent to use all available sources to expand the pool of donor organs, and our data 
supports the practice of using extended-criteria DCD grafts based on donor age. Notwithstanding that, 
*Abstract
clinicians should be aware that HCV recrudescence is more rapid in DCD recipients, and early post-
transplant anti-viral therapy is indicated to prevent graft injury. 
Highlights 
 This article reports the experience of the UK's largest liver transplant centre of patients receiving 
donation after circulatory death (DCD) liver grafts and compares their outcomes to a matched 
cohort of individuals receiving donation after brainstem death (DBD) liver grafts for hepatitis C 
related liver disease.  
 HCV recurrence was more rapid in DCD recipients; other risk factors were CMV infection and 
steroid use post-transplantation. 
 5-year patient and graft survival, and rates of biliary complications, were equal in both groups.  
 On average DCD donor age was 10 years older than in other published cohorts, supporting the 
uses of extended-criteria DCD grafts. 
 In an era of highly effective DAA therapy, rapid HCV recrudescence in grafts from DCD donors 
should not compromise long term morbidity or mortality, but clinicians should be aware that 
early post-transplant anti-viral therapy is indicated to prevent graft injury. 
*Research Highlights
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HCV recurrence occurs earlier in patients receiving donation after circulatory death (DCD) liver 
transplants compared with those receiving donation after brainstem death (DBD) grafts. 
 
Introduction: HCV-related cirrhosis remains the commonest indication for liver transplantation 
worldwide, yet few studies have investigated the impact of DCD graft use on HCV recurrence and 
patient outcomes. DCD grafts have augmented the limited donor organ pool and reduced wait-list 
mortality, although concerns regarding graft longevity and patient outcome persist. 
Methods: This was a single centre study of all HCV+ adults who underwent DCD liver transplantation 
between 2004 and 2014. 44 HCV+ patients received DCD grafts, and were matched with 44 HCV+ 
recipients of DBD grafts, and their outcomes examined. 
Results: The groups were matched for age, sex, presence of HCC; no significant differences were found 
between the group’s donor or recipient characteristics.  Paired and unpaired analysis demonstrated that 
HCV recurrence was more rapid in recipients of DCD organs compared with DBD grafts (408 vs 657 days; 
p=0.006). There were no significant differences in graft survival, patient survival, or rates of biliary 
complications between the cohorts despite DCD donors being 10 years older on average than those 
used in other published experience. 
Conclusions: In an era of highly effective DAA therapy, rapid HCV recrudescence in grafts from DCD 
donors should not compromise long term morbidity or mortality.  In the context of a rising wait-list 
mortality it is prudent to use all available sources to expand the pool of donor organs, and our data 
supports the practice of using extended-criteria DCD grafts based on donor age. Notwithstanding that, 
clinicians should be aware that HCV recrudescence is more rapid in DCD recipients, and early post-
transplant anti-viral therapy is indicated to prevent graft injury.  
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Introduction 
Orthoptic liver transplantation (OLT) is a life-saving intervention for patients with end-stage liver 
disease, but the availability of transplantation is limited by the number of organs available. Current NHS 
waiting list mortality is approximately 17% in the UK with the highest on-list mortality occurring in the 
first 6 months after listing and, whilst the number of patients registered for transplantation continues to 
rise, the number of conventional DBD livers available for grafting has remained relatively static (1).  The 
increased use of donation after circulatory death (DCD) organs is a pragmatic response to the problem 
and seeks to implant livers that would previously not have been available for transplantation and, by 
increasing the available donor pool, seeks to reduce patient mortality and shorten the time to 
transplantation on waiting lists (2-5). Notwithstanding this, despite growing expertise in the selection 
and use of DCD grafts, there are concerns regarding a perceived inferior medium and long term graft 
and patient survival in DCD recipients, particularly in those DCD grafts harvested from older donors (6). 
In the UK, liver disease secondary to hepatitis C virus (HCV) infection and/or alcohol use remain the 
primary indications for liver transplantation (1).  Few studies however have investigated the impact of 
DCD graft use on recurrence of HCV and long-term outcomes.   
Birmingham is the largest liver transplant unit in Europe, grafting approximately 250 patients per year, 
and has the highest rate of graft utilisation in the UK (1). There has been steady growth in the utilisation 
of DCD grafts, such that 29% of adult liver transplants undertaken in Birmingham in 2015 used DCD-
derived livers. Transplantation for hepatitis C related cirrhosis comprises 14% of all indications for liver 
replacement in Birmingham. Between January 2004 and 2014, 208 DCD grafts were used for liver 
transplantation (15% of total transplant activity), and 49 of these were for HCV related liver disease. 
We retrospectively examined the outcomes of all HCV positive patients undergoing DCD liver 
transplantation, and compared them with a matched cohort of HCV positive patients receiving donation 
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after brainstem death (DBD) grafts. Particular attention was paid to patient and graft survival, HCV 
recurrence, and biliary complications. 
 
Methods 
This was a retrospective matched case-controlled single centre study of all HCV positive adults who 
underwent controlled (Maastricht III) DCD liver transplantation between January 2004 and January 2014 
at the Queen Elizabeth Hospital, Birmingham.  Of the 1384 adult transplants completed in this period, 
DCD grafts were used in 208 patients, 49 for HCV related liver disease.  Five patients were excluded 
because they were found to have been successfully treated for HCV prior to transplantation.  A cohort of 
44 HCV positive patients who received DCD grafts was identified and matched with 44 HCV positive 
recipients of DBD grafts during the same time period.  Patients were matched with regards to age, sex, 
and the presence of hepatocellular carcinoma (HCC).  
Other characteristics compared between the two groups were donor age, model for end-stage liver 
disease score (MELD), the United Kingdom model for end-stage liver disease (UKELD) score at time of 
transplantation, HCV genotype and viral load, use of renal replacement therapy post-operatively, 
episodes of rejection, and use of antiviral treatment pre-and post-transplantation.  Outcomes measured 
were patient and graft survival, time to HCV recurrence, and biliary complications (ischaemic 
cholangiopathy, anastomotic strictures, bile leaks).  
The primary endpoint was HCV recurrence and secondary endpoints were patient and graft survival, and 
biliary complications. The diagnosis of HCV recurrence was made with positive HCV PCR supported by 
either biopsy findings (chronic portal inflammation, with or without portal lymphoid aggregates, 
together with necroinflammatory and ductular-type interface activity) (7), or, in the context of 
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significantly abnormal liver function tests (LFTs) (bilirubin>30mg/dL, AST>100units/L), a high HCV titre 
and a high level of clinical suspicion.  Biopsies were not routinely performed unless clinically indicated. 
All patients were initially treated with triple immunosuppression therapy including a calcineurin 
inhibitor (tacrolimus or cyclosporine), anti-proliferative agent (mycophenolate mofetil or azathioprine) 
and steroids (hydrocortisone in the immediate post-operative days followed by conversion into 
prednisolone 20 mg/ day tapered over 3 months).  
Episodes of rejection requiring augmentation of steroid dose were recorded.  HCV recurrence was 
treated according to clinical need with the standard of care therapy that existed at that time - either 
dual therapy (interferon and ribavirin), triple therapy (interferon, ribavirin and telapravir) or using 
regimens of direct acting antiviral therapy.   
 
Statistical Analysis 
Recipient and donor characteristics were compared among the groups using Fisher’s exact test for 
categorical variables and Student’s t-tests or Mann-Whitney tests, as appropriate, for continuous 
variables.  Values are expressed as frequencies and percentages for categorical data, and mean and 
standard deviation (SD), or median and interquartile range for continuous data. 
Patient survival, graft survival, and HCV recurrence among the patient groups were compared with 
Kaplan-Meier plots and log-rank tests. Graft survival was timed from the date of transplantation to the 
date of re-transplantation or death (whichever came first) and was censored for the date of the end of 
the study period or for the date of the last correspondence for patients lost to follow-up. Patient 
survival was time from the date of transplantation to the date of death and was censored for the date of 
the end of the study period or for the date of the last correspondence for patients lost to follow-up. HCV 
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recurrence was timed from the date of transplantation to the date of diagnosis and was censored for 
the date of the end of the study period or for the date of the last correspondence for patients lost to 
follow-up, the date of death, or the date of re-transplantation. 
Unconditional and conditional Cox regression were used in the univariate analysis of predictors of 
patient survival, graft survival, and HCV recurrence. 
Biliary complications were compared between the two groups using Fisher’s exact test. 
Significance was defined at a P value < 0.05. Data were analysed using IBM SPSS Statistics for Windows, 
Version 22.0. Armonk, NY: IBM Corp. 
 
Results  
The two groups were well matched for age, sex, and presence of HCC.  The mean age at transplant was 
55 years; 70 of 88 (80%) patients were male.  No significant differences were found between the groups 
for donor age, HCV genotype, CMV infection post-transplant, immunosuppression regimens, and rates 
of rejection requiring steroids (see table 1).  The Model for End-Stage Liver Disease (MELD) score at 
transplantation was higher in DBD recipients than those receiving DCD grafts (median=13 versus 10; 
p=0.282) which would be consistent with our usual practice of offering DCD grafts to  recipients with 
higher levels of fitness and physical functionality. As one might expect, this cohort had a lower UKELD 
score, and the difference between the groups was statistically significant (median=52 versus 50; 
p=0.020, see table 1).  
Overall the patients were followed up for a median of 3.8 years (range 1.1-12.6).  Five year patient 
survival was 77.3% and 72.2% for DCD and DBD recipients, respectively (p=0.709).  Five year graft 
survival was 70.2% for DCD recipients, versus 75.0% for DBD recipients (p=0.802).  Causes of death were 
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HCC recurrence in nine patients, sepsis or pneumonia in six, recurrent hepatitis C in four, brain death in 
two, and multiple causes for the remaining seven patients (see table 2). The cause of death is unknown 
for two patients.  Seven patients had early graft failure post-transplantation (range 2 days to 3 months) 
and all were successfully re-grafted.  Four were DBD grafts; two failed secondary to refractory acute 
cellular rejection within one month of transplantation, the third developed early hepatic artery 
thrombosis (HAT) and there was primary non function in the forth. Two DCD grafts failed secondary to 
primary non function and the third also had early HAT. 
Rates of biliary complications were low and comparable between the two cohorts, with a slightly 
increased incidence of ischaemic cholangiopathy in the DCD recipient cohort, not reaching statistical 
significance (p=0.594). 
Paired and unpaired analysis demonstrated that HCV recurrence was more rapid in recipients of DCD 
compared with DBD grafts (408 versus 657 days; p=0.006).  CMV infection (p=0.021) and rejection 
requiring steroid augmentation (p=0.030) were both risk factors for recurrence. There was no difference 
in HCV recurrence rate between viral genotypes on direct comparison between paired genotypes or all 
four groups (p=0.118). 
Twenty-six patients had aggressive HCV recurrence (recrudescence within one year of transplantation 
requiring antiviral therapy) and were reviewed in greater detail. Use of DCD grafts (p=0.010), as well as 
CMV infection (p=0.001) were again showed to be risk factors for recurrence in this cohort. No other 
factors were found to found to be significant for aggressive recurrence, including recipient age 
(p=0.237), sex (p=0.248), genotype (p=0.233), MELD score at the time of transplantation (p=0.615), viral 
load pre transplant (p=0.451), or viral load at one year post transplant (p=0.836), or even steroid use 
(p=0.070).  
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Of the total 88 patient cohort, seven patients had CMV infection, all within 5 months of transplantation. 
Six of these patients were CMV positive prior to transplantation and all received organs from CMV 
positive liver donors.  It was unclear whether the CMV negative recipient was compliant with 
prophylactic valganciclovir.  One patient who developed abnormal LFTs was treated successfully with 
valganciclovir, another was treated for CMV colitis; in four patients the infection was considered 
clinically insignificant and treatment was not initiated; it is unclear whether the remaining patient was 
treated.   
12 patients had acute cellular rejection requiring steroid augmentation at a median of 7 days post-
transplant (range 2 days – 16 months).  All 12 patients had received standard immunosuppression and 
had acceptable serum tacrolimus levels prior to the episode of rejection, except one patient who 
developed acute rejection at 16 months secondary to poor medication compliance, and one patient for 
whom tacrolimus initiation post-transplant was delayed. 
Forty-eight patients received antiviral treatment prior to transplantation (21 DBD recipients and 27 DCD 
recipients); all had treatment failure (poor viral response, post-treatment relapse, treatment intolerance 
or liver decompensation). Thirty-one patients did not receive treatment (15 DBD recipients, 16 DCD 
recipients), and for 9 patients pre-transplantation treatment status was unclear from electronic records 
(8 of whom were DBD recipients).  
Post-transplantation, 44 patients have received 46 courses of antiviral therapy. Among the 44 DBD liver 
recipients, 1 patient received single therapy with interferon, 10 received dual therapy (interferon or 
PEG-interferon and ribavirin), 7 received triple therapy (PEG-interferon, ribavirin, telapravir or PEG-
interferon, ribavirin, sofosbuvir), 1 received dual therapy followed by triple therapy, and 2 have 
completed treatment with direct antiviral therapy (DAA).  A sustained virological response (SVR) was 
achieved in 14 of the 21 (66.7%) DBD recipients that were treated within the study period. For those 
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patients who received DCD grafts, 10 patients received dual therapy, 10 received triple therapy, and 6 
patients have completed DAA therapy, including 2 patients who received dual therapy followed by 
DAAs, and one who received triple therapy and DAAs. SVR was achieved in 17 of 23 patients (73.9%). It 
is worth noting that the majority of these patients were treated in a pre-DAA era. 
Twenty-six patients were considered to have early aggressive recurrence (abnormal liver function with 
positive viral titre and evidence of fibrosis) within 2 years of transplantation. Fourteen were successfully 
treated with antiviral therapy and none of these patients have subsequently experienced liver related 
mortality or morbidity, other than one patient who developed recurrent HCC and died 5 years post-
transplant.  Nine patients failed antiviral therapy; 3 died as a result of  recurrent HCV at a mean of 500 
days post-transplantation (range 192-947 days), 1 died due to  recurrent HCC, 1 died from 
gastrointestinal bleed, 2 were reassessed for liver transplantation, one of whom was relisted, and both 
are still alive.  Three patients were not treated; 1 has died of HCC recurrence, 1 is alive, and 1 lives 
abroad. No patients in this cohort have required re-transplantation for HCV recidivism.    
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Discussion 
HCV related liver disease remains the primary indication for liver transplantation worldwide. Survival is 
known to be worse than other indications for liver replacement, primarily due to HCV recrudescence 
shortening graft survival (8). We are already seeing how highly effective direct acting antiviral therapy 
reduces short to medium term morbidity mortality in both pre and post-transplant populations, and is 
likely that over the next 10 years patient and graft survival should rise to match the best outcomes 
achieved in liver transplantation for other indications.  Nevertheless, demand for organs remains high 
and grafts that were once considered more marginal (such as DCD-derived organs) provide a valuable 
resource that will help to reduce wait-list times and mortality. 
Few studies have evaluated the effect of DCD liver organs in HCV positive recipients.  A recent meta-
analysis by Wells et al included only 3 single centre studies with mixed outcomes (9). One of those was a 
retrospective study carried out by Taner et al, which compared 77 HCV positive DCD liver recipients with 
77 matched DBD recipients and showed no difference in graft or patient survival between the two 
groups.  Multi-variate analysis demonstrated that a higher MELD score and the occurrence of CMV 
infection within the first year of transplantation reduced survival in all recipients:  genotype 1 infection 
and moderate to severe rejection were both  risk factors for the development of stage 2 fibrosis post-
transplantation, but these risks were not specifically associated with the use of DCD grafts (10).  A 
similar but smaller study by Tao et al suggested a trend toward poorer outcomes in DCD liver recipients 
compared with the DBD cohort, but statistical significance was not reached, and no difference in HCV 
recurrence was seen between the two matched groups.  CMV infection and acute cellular rejection did 
increase the risk of HCV recurrence in both groups, as well as donor age (11).   
Only the paper by Hernandez-Alejandro, which reported the outcomes of 17 DCD HCV positive liver 
recipients, suggested a significantly reduced graft survival, as well as increased HCV recurrence in these 
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patients (12).  Interestingly, Wells’ meta-analysis concluded that the rates of primary non-function were 
higher in HCV positive recipients of DCD grafts compared to DBD grafts, but that overall graft and 
patient survival, biliary complications, and HCV recurrence rates, were equivalent (9).  
These findings are further supported by a retrospective study of two large US databases, the United 
Network for Organ Sharing and the Organ Procurement and Transplantation Network, which 
demonstrated inferior outcomes for all patients receiving DCD grafts compared with DBD grafts, but the 
difference between the groups was less significant for the HCV positive cohort compared with HCV 
negative recipients with other indications for liver transplantation (6).  A similar study interrogating the 
outcomes of all liver recipients at our centre demonstrated that rates of ischaemic cholangiopathy and 
acute kidney injury were higher in DCD recipients, but that there was no difference in graft or patient 
survival within a matched cohort (13).  
Our results for graft and patient survival are consistent with other single centre retrospective studies, 
but show more rapid HCV recrudescence in DCD recipients.  This was reflected in a higher proportion of 
those individuals requiring DAA therapy.  CMV infection and steroid augmentation for episodes of 
rejection were both risk factors for HCV recrudescence, as has been previously demonstrated.  There 
were no differences between the rates of primary non-function or acute kidney injury, although there 
was a trend towards increased rates of biliary complications in the DCD cohort which would fit with 
published experience; that the differences were not more stark is probably a reflection of system 
learning and improved patient selection in DCD graft recipients which has minimised the impact on graft 
survival and limited post-op complications. 
It is worth noting that the mean DCD (and DBD) donor age in our study was over 10 years older than the 
studies carried out by Taner and Tau (48.0 years for DBD grafts and 49.3 years for DCD donors in our 
study, compared with 37.6 and 37.7 years in Taner’s study, and 38.1 and 37.9 years in the paper by Tau 
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et al, for DBD and DCD grafts, respectively (10, 11)).  Despite using more extended-criteria grafts, we 
have demonstrated comparable long term outcomes, demonstrating that it is safe to extend DCD (and 
DBD) criteria by using liver-grafts taken from older donors. 
We recognise that our study has the limitation of being a moderate-sized, single centre retrospective 
analysis, but the well matched groups and uniformity of surgical practice have resulted in a detailed 
analysis that provides compelling evidence to support the premise that the use of DCD organs in HCV 
positive recipients is both justifiable and safe.  
 
Conclusions 
In the era of potent DAA therapy, rapid HCV recrudescence in grafts from DCD donors should not 
compromise long term morbidity or mortality. HCV remains the primary reason for liver transplantation 
worldwide and, in an era of burgeoning wait-list mortality, it is prudent to use all available sources to 
expand the pool of donor organs, including use of grafts from donation after circulatory death. Clinicians 
should be aware that HCV recrudescence is more rapid in this group and that early post-transplant anti-
viral therapy is indicated to prevent graft injury. The use of DCD livers provides an invaluable pool of 
organs which, with improvements in graft preservation, will provide equivalent outcomes to HCV+ 
patients receiving conventional DBD livers.  
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Table 1. Characteristics of HCV positive recipients of DCD and DBD donors 
Characteristic DCD (n=44) DBD (n=44)     р Value 
Recipient Age 55.4 (+/-6.5) 55.2 (+/-6.7)        0.917 
Recipient gender M:F 35(80%): 9 (20%) 35 (80%): 9 (20%) 1.000 
HCC in explant 25 25 1.000 
MELD score 10 (8-18) 13 (10-17) 0.282 
UKELD  50 (46-55) 52 (50-55) 0.020 
HCV Genotype   0.118 
1 17 20  
2 2 0  
3 24 19  
4 0 3  
Viral Load at transplantation 626997 (215-
2030007) 
70055 (3727-
341383) 
0.044 
Donor age (yrs) 49.3 (+/-16.2) 48.0 (+/-13.5) 0.685 
Incidence of Primary non-function 2 3 1.000 
Days in ITU post–transplant 3 (2-4) 3 (2-4) 0.997 
Renal Replacement Therapy post-
transplant 
8 (18%) 12 (27%) 0.446 
Episodes of rejection requiring steroids 7 (15.9%) 5 (11.4%) 0.757 
CMV infection within 1st year of 
transplantation 
4 3 1.000 
Biliary complications (total) 8 5 0.549 
Ischaemic cholangiopathy 5 1 0.202 
Strictures 3 2 - 
Other 0 2 - 
Number of biopsies taken 34 25 0.069 
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Table 2. Causes of death for DBD and DCD recipients 
Cause of death DBD recipient DCD recipient 
Recurrent HCC 4 5 
Recurrent Hepatitis C 2 2 
Sepsis/pneumonia 4 2 
Hepatic artery thrombosis 0 1 
Chronic rejection 0 1 
Brain death 2 0 
Renal failure 0 1 
Gastrointestinal bleed 1 0 
Ischaemic heart disease 0 1 
De novo malignancy 1 0 
Suicide 0 1 
Unknown 1 1 
 
 
Table 3. Antiviral treatment post-transplant 
Treatment DBD recipient  DCD recipient SVR achieved 
Single therapy 1 0 0 
Duel therapy 10 10 11 
Triple therapy 7 10 12 
DAAs 2 6 8 
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Figure 1. Patient survival in DBD versus DCD recipients 
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Figure 2. Graft survival in DBD vs DCD recipients 
 
Figure 3.  Hepatitis C recrudescence in DBD vs DCD recipients 
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